Keyphrases
Osteoarthritis
100%
Meta-analysis of Randomized Controlled Trials
100%
Lumiracoxib
100%
Cardiovascular Safety
100%
Placebo
50%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
50%
Meta-analysis
25%
Cardiovascular Outcomes
25%
Trialists
25%
Antiplatelet
25%
No Significant Difference
12%
Confidence Interval
12%
Cardiovascular Risk
12%
Myocardial Infarction
12%
Cardiovascular Mortality
12%
Pooled Odds Ratios
12%
Peer-reviewed Journals
12%
Cardiovascular Endpoints
12%
PubMed Search
12%
Novartis
12%
Right to Use
12%
Search Criteria
12%
Nursing and Health Professions
Meta Analysis
100%
Osteoarthritis
100%
Lumiracoxib
100%
Placebo
50%
Nonsteroid Antiinflammatory Agent
50%
Odds Ratio
12%
Confidence Interval
12%
Heart Infarction
12%
Medline
12%
Cerebrovascular Accident
12%
Cardiovascular Risk
12%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Osteoarthritis
100%
Lumiracoxib
100%
Placebo
50%
Non-Steroidal Anti-Inflammatory Drug
50%
Antiplatelet
25%
Heart Infarction
12%
Cerebrovascular Accident
12%
Cardiovascular Risk
12%
Veterinary Science and Veterinary Medicine
Osteoarthritis
100%
Lumiracoxib
100%
Non-Steroidal Anti-Inflammatory Drug
50%
Myocardial Infarction
12%
Biochemistry, Genetics and Molecular Biology
Randomized Controlled Trial
100%
Lumiracoxib
100%
Medline
12%